09.19.08
Laureate Pharma, Inc. is increasing its manufacturing capacity with the addition of two Single-Use Bioreactors (S.U.B.), a 250L and a 1000L S.U.B. The S.U.B. is a single-use alternative to stirred tank bioreactors. The S.U.B. consists of a permanent stainless steel outer support container and a Bioprocess Container (BPC), integrated with an existing bioreactor control system. According to the company, this provides a flexible, rapid and economic option to update or increase the bioreactor capacity. The S.U.B. will supplement the company’s current single-use bioreactors, Wave Bioreactors and hollow-fiber systems, as well as the conventional stainless steel stirred-tank bioreactors.
“We are excited about adding the S.U.B. to increase our bioreactor capacity. It is a scalable technology that will support the demand from our growing client base and meet their needs and manufacturing objectives,” said Robert J. Broeze, Ph.D., president and chief executive officer of Laureate. “The HyClone S.U.B. provides us with all the advantages of single-use bioprocessing, while maintaining aspect ratios and agitation mechanisms comparable to traditional stainless steel stirred-tank bioreactors.”
“We are excited about adding the S.U.B. to increase our bioreactor capacity. It is a scalable technology that will support the demand from our growing client base and meet their needs and manufacturing objectives,” said Robert J. Broeze, Ph.D., president and chief executive officer of Laureate. “The HyClone S.U.B. provides us with all the advantages of single-use bioprocessing, while maintaining aspect ratios and agitation mechanisms comparable to traditional stainless steel stirred-tank bioreactors.”